SciSparc publishes patent application in collaboration with Clearmind Medicine

SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), the publication of an international patent application under the Patent Cooperation Treaty for the combination of Ibogaine with N-Acylethanolamines. Ibogaine is the major constituent of the root of Tabernanthe iboga, a shrub commonly found in Western and Central Africa. Ibogaine use in human clinical trials suggests efficacy in the treatment of opioid use disorder, cocaine use disorder, and other substance use disorders, suggesting that Ibogaine is a potentially useful anti-addictive agent. Under this collaboration, the SciSparc and Clearmind are researching combination therapies that integrate psychedelic molecules with the N-acylethanolamines family, including Palmitoylethanolamide. To date, thirteen patents related to this collaboration have been filed by Clearmind with the U.S. Patent and Trademark Office, as well as in several other global jurisdictions.